SCHEMBL2056285

SCHEMBL2056285

CCc1nc(-c2ccc(Cl)cc2)co1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 11/20 0.51
LTA4H P09960 1/20 0.47
S1PR3 Q99500 7/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
ENPP3 O14638 2/20 0.41
ENPP1 P22413 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
RAB9A P51151 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
SLC22A1 O15245 1/20 0.38
DHFR P00374 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL10435684 0.89 S1PR1 (0.50) S1PR1LTA4HS1PR3ALDH1A1SMN1; SMN2
SCHEMBL13732790 0.86 S1PR1 (0.54) S1PR1LTA4HS1PR3MEN1ALDH1A1
SCHEMBL10711669 0.82 LTA4H (0.46) S1PR1LTA4HS1PR3MEN1ALDH1A1
SCHEMBL203844 0.82 LTA4H (0.47) S1PR1LTA4HS1PR3LMNAENPP3
SCHEMBL9833295 0.82 NOTUM (0.51) S1PR1LTA4HS1PR3MEN1ALDH1A1
SCHEMBL28025184 0.82 S1PR1 (0.51) S1PR1S1PR3MEN1KMT2AENPP3
SCHEMBL9198367 0.82 S1PR1 (0.55) S1PR1S1PR3ALDH1A1ENPP3ENPP1
SCHEMBL9880273 0.81 S1PR1 (0.50) S1PR1S1PR3MEN1KMT2AENPP3
SCHEMBL28025221 0.81 S1PR1 (0.57) S1PR1S1PR3ALDH1A1ENPP3ENPP1
SCHEMBL17887308 0.78 LTA4H (0.44) S1PR1LTA4HS1PR3MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 S1PR1 1852/4885LTA4H 3093/4885S1PR3 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.